What is HC Wainwright's Forecast for ENTA Q1 Earnings?

Enanta Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright forecasts Enanta Pharmaceuticals will lose $0.49 per share in Q1 2027. The firm maintains a Buy rating and a $20 price target, and estimates a $2.14-per-share loss for FY2027.
  • Enanta’s latest quarter came in below expectations: it reported a loss of $0.81 per share versus the consensus loss of $0.72, while revenue of $12.87 million also fell short of estimates.
  • Analyst sentiment is mixed: MarketBeat reports an average Hold rating and a $20 average price target, with two Buy ratings and one Sell rating.
  • MarketBeat previews top five stocks to own in December.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for Enanta Pharmaceuticals in a research note issued on Tuesday, November 17th. HC Wainwright analyst B. Folkes forecasts that the biotechnology company will post earnings per share of ($0.49) for the quarter. HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Enanta Pharmaceuticals' current full-year earnings is ($2.50) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals' Q2 2027 earnings at ($0.53) EPS, Q3 2027 earnings at ($0.55) EPS, Q4 2027 earnings at ($0.57) EPS, FY2027 earnings at ($2.14) EPS, FY2028 earnings at ($2.67) EPS, FY2029 earnings at ($1.95) EPS and FY2030 earnings at ($1.62) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.09). The company had revenue of $12.87 million for the quarter, compared to analyst estimates of $14.62 million. Enanta Pharmaceuticals had a negative net margin of 108.33% and a negative return on equity of 59.48%.

A number of other analysts also recently commented on the company. Wall Street Zen downgraded Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Sunday, October 11th. Weiss Ratings reissued a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a report on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $20.00.

Read Our Latest Report on ENTA

Enanta Pharmaceuticals Stock Down 5.3%

NASDAQ ENTA opened at $8.23 on Thursday. Enanta Pharmaceuticals has a 1-year low of $8.10 and a 1-year high of $17.15. The business has a 50 day moving average price of $11.68 and a 200 day moving average price of $13.03.

Institutional Trading of Enanta Pharmaceuticals

Several large investors have recently modified their holdings of the business. Spruce Street Capital LP acquired a new position in shares of Enanta Pharmaceuticals during the 2nd quarter worth approximately $15,873,698. Jupiter Topco LLC purchased a new stake in Enanta Pharmaceuticals in the 2nd quarter valued at approximately $53,252,000. Janus Henderson Group PLC lifted its stake in Enanta Pharmaceuticals by 1.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company's stock valued at $47,717,000 after buying an additional 54,396 shares in the last quarter. Ieq Capital LLC purchased a new stake in Enanta Pharmaceuticals in the 2nd quarter valued at approximately $561,000. Finally, BlackRock Inc. acquired a new stake in Enanta Pharmaceuticals during the 2nd quarter valued at $47,304,000. 94.99% of the stock is currently owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

(Get Free Report)

Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta's work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company's history of applying its drug-discovery expertise to antiviral therapies.

Read More

Earnings History and Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Enanta Pharmaceuticals Right Now?

Before you consider Enanta Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enanta Pharmaceuticals wasn't on the list.

While Enanta Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines